CAPTEM pills after brain radiation for newly diagnosed glioblastoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial studies whether taking two chemotherapy pills (capecitabine and temozolomide) after the initial 6-week radiation-and-chemo phase can help people with newly diagnosed glioblastoma. It aims to test safety and early effectiveness right before the usual maintenance temozolomide phase.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent and clearly understand the study.
- Your glioblastoma diagnosis was confirmed by pathology (biopsy/surgery results).
- You finished the first 6 weeks of standard radiation plus chemo, and you have not started the usual next-phase temozolomide maintenance yet.
- You can swallow pills and your body can tolerate oral chemotherapy based on labs and exam.
- Your blood counts, kidney, and liver tests are strong enough before starting treatment.
- You are age 18–74, expected to live more than 3 months, and your function level is good (KPS 70 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a chemotherapy drug called temozolomide before radiation therapy to people with a newly diagnosed high-grade brain tumor. The goal is to see if this approach can help control the tumor better.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial tests a combination of two oral medications (vebreltinib and temozolomide) after surgery for a specific type of brain cancer called glioblastoma. The goal is to see if this combination can help stop the cancer from growing back.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
This trial tests whether adding an experimental drug called liposomal transcrocetin (L-TC) to the standard treatment of radiation and temozolomide chemotherapy helps people with newly diagnosed glioblastoma. It aims to see if the combination improves outcomes compared to standard care alone.
This trial tests whether adding the drug ruxolitinib to standard radiation and chemotherapy (temozolomide) helps people with a newly diagnosed brain tumor called glioblastoma. It aims to see if the combination keeps the tumor from growing longer than the standard treatment alone.
Hear when a new Glioblastoma Multiforme (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.